Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates
Royalty Pharma (RPRX) delivered earnings and revenue surprises of +3.64% and +5.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?